Amyotrophic Lateral Sclerosis (ALS)

Reactivated Virus May Contribute to ALS

New research suggests that the DNA of a normally dormant virus may be playing a role in causing amyotrophic lateral sclerosis (ALS).

If the findings are confirmed, they could ultimately have implications for treatment of the disease.

About the HERV-K virus

ALS Research Briefs

Loss of TDP43's normal function could be ALS contributor

MDA Awards $2 Million to ALS TDI

MDA has awarded $2 million to the ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., to help scientists complete the preclinical testing of four promising new compounds in ALS TDI's drug development pipeline. 

The grant, made through MDA's Augie's Quest ALS fundraising initiative, raises MDA's total grant contributions to ALS TDI to more than $23.4 million since 2007.

About the new funding

ALS TDI plans to test the four new compounds in the SOD1 ALS research mouse model.

ALS Therapy Development Institute: Looking Ahead to 2011

New space for research, new mouse models of ALS and new technology to screen therapeutic agents all will play a role in 2011 at the ALS Therapy Development Institute (ALS TDI), said Steve Perrin, ALS TDI chief scientific officer and CEO, in the biotech's monthly webinar in January.

Accelerate ALS research

Perrin listed a number of specific milestones the Institute hopes to reach in 2011.

Eight New Grants Bolster MDA's Battle Against ALS

MDA has awarded eight new grants totaling nearly $2.5 million to fund research projects focused on uncovering the causes of, and developing therapies for, ALS. The effective start date for the grants was Feb. 1, 2011.

MDA Awards $13.5 Million in Research Grants

The Muscular Dystrophy Association has awarded 44 grants totaling $13.5 million to support research efforts aimed at advancing understanding of disease processes and uncovering new strategies for treatments and cures of muscular dystrophy and the more than 40 other diseases in the Association’s program.

The new grants were reviewed by MDA’s Scientific and Medical Advisory Committees, and approved by MDA’s Board of Directors at its December meeting.

Isis Hosts Webinar for SOD1-Rx Trial

Isis Pharmaceuticals hosted an interactive webinar Wednesday, March 2, 2011, at 12 noon Eastern Standard Time, to help prospective participants understand its MDA-supported, phase 1 study of ISIS-SOD1-Rx for people with familial amyotrophic lateral sclerosis (ALS) due to mutations in the SOD1 gene.

For those unable to participate during the live webinar, a replay will be available for a limited time on the Isis website.

Clinical Trial Info: Ceftriaxone in ALS

Researchers conducting a clinical trial of the antibiotic ceftriaxone in amyotrophic lateral sclerosis (ALS) currently are recruiting participants at 57 locations across the United States and Canada.

ALS Experts: Keep the Weight On

People with amyotrophic lateral sclerosis (ALS) should go ahead and eat foods high in fat and calories, but they also need to eat healthy foods as well, say experts on ALS nutrition who participated in an MDA-sponsored webinar on January 11, 2011.

ALS Research Briefs

Spirulina supplement seems to help ALS mice

A study of 15 mice with a genetic mutation that causes an ALS-like disease suggests that the nutritional supplement spirulina may have some protective effects on motor neurons, the main cells that degenerate in ALS.